Skip to main navigation Skip to search Skip to main content

Ablation of AMP-activated protein kinase α1 and α2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo

  • G. Sun
  • , A. I. Tarasov
  • , J. McGinty
  • , A. McDonald
  • , G. Da Silva Xavier
  • , T. Gorman
  • , A. Marley
  • , P. M. French
  • , H. Parker
  • , F. Gribble
  • , F. Reimann
  • , O. Prendiville
  • , R. Carzaniga
  • , B. Viollet
  • , I. Leclerc
  • , G. A. Rutter

Research output: Contribution to journalArticlepeer-review

Abstract

Aims/hypothesis: AMP-activated protein kinase (AMPK) is an evolutionarily conserved enzyme and a target of glucose-lowering agents, including metformin. However, the precise role or roles of the enzyme in controlling insulin secretion remain uncertain. Methods: The catalytic α1 and α2 subunits of AMPK were ablated selectively in mouse pancreatic beta cells and hypothalamic neurons by breeding Ampkα1 [also known as Prkaa1]-knockout mice, bearing floxed Ampkα2 [also known as Prkaa2] alleles (Ampkα1 -/-,α2 fl/fl,), with mice expressing Cre recombinase under the rat insulin promoter (RIP2). RIP2 was used to express constitutively activated AMPK selectively in beta cells in transgenic mice. Food intake, body weight and urinary catecholamines were measured using metabolic cages. Glucose and insulin tolerance were determined after intraperitoneal injection. Beta cell mass and morphology were analysed by optical projection tomography and confocal immunofluorescence microscopy, respectively. Granule docking, insulin secretion, membrane potential and intracellular free Ca2+ were measured with standard techniques. Results: Trigenic Ampkα1 -/-,α2 fl/fl expressing Cre recombinase and lacking both AMPKα subunits in the beta cell, displayed normal body weight and increased insulin sensitivity, but were profoundly insulin-deficient. Secreted catecholamine levels were unchanged. Total beta cell mass was unaltered, while mean islet and beta cell volume were reduced. AMPK-deficient beta cells displayed normal glucose-induced changes in membrane potential and intracellular free Ca2+, while granule docking and insulin secretion were enhanced. Conversely, βAMPK transgenic mice were glucose-intolerant and displayed defective insulin secretion. Conclusions/interpretation: Inhibition of AMPK activity within the beta cell is necessary, but not sufficient for stimulation of insulin secretion by glucose to occur. AMPK activation in extrapancreatic RIP2.Cre-expressing cells might also influence insulin secretion in vivo.

Original languageEnglish
Pages (from-to)924-936
Number of pages13
JournalDiabetologia
Volume53
Issue number5
DOIs
Publication statusPublished (in print/issue) - 1 May 2010

Funding

Acknowledgements This work was supported by grants to G. A. Rutter from the Wellcome Trust (Programme Grant 081958/2/07/Z), The European Union (FP6 “Save Beta”), the Medical Research Council (G0401641) and National Institutes of Health (RO1 DK071962-01), as well as by a JDRFI Post-Doctoral Fellowship to A. I. Tarasov. We thank B. Kola (Queen Mary, University of London) for useful discussion, and P. Meda (University of Geneva) and B. Thorens (University of Lausanne) respectively for the kind provision of anti-ZO-1 and anti-GLUT2 antibodies. L. Lawrence is thanked for the preparation of pancreatic slices.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • AMPK
  • Beta cell
  • Insulin secretion
  • Islet
  • Knockout
  • RIP.Cre

Fingerprint

Dive into the research topics of 'Ablation of AMP-activated protein kinase α1 and α2 from mouse pancreatic beta cells and RIP2.Cre neurons suppresses insulin release in vivo'. Together they form a unique fingerprint.

Cite this